Nature Biotechnology's annual survey of public biotechnology companies reveals that it was “business as usual” for the biotechnology sector, despite the year's economic downturn.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lähteenmäki, R., Fletcher, L. Public biotechnology 2001—the numbers. Nat Biotechnol 20, 551–555 (2002). https://doi.org/10.1038/nbt0602-551
Issue Date:
DOI: https://doi.org/10.1038/nbt0602-551
This article is cited by
-
The biotechnology bubble machine
Nature Biotechnology (2003)
-
Public biotechnology 2002—the numbers
Nature Biotechnology (2003)